Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07559136 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Completion date: Mar 2027 to Apr 2027 · Eligibility criteria expanded, about 15 words · Site details revised Show 3 more changesShow less
    • Completion date: Mar 2027 to Apr 2027
    • Eligibility criteria expanded, about 15 words
    • Site details revised
  2. Recruitment opened Primary completion pushed from Jan 2027 to Feb 2027 · Completion date: Feb 2027 to Mar 2027 · Start date changed from estimate of May 2026 to Jun 12, 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion pushed from Jan 2027 to Feb 2027
    • Completion date: Feb 2027 to Mar 2027
    • Start date changed from estimate of May 2026 to Jun 12, 2026
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
Trial Details
NCT Number NCT07559136
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Overweight and Obesity
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov